ISIS : Analysis & Opinions

  1. These stocks had big price moves recently, and cosidering where the price is from a technical perspective, further big moves are expected.

    Big Mover Stocks With More Big Move Potential

    May 26, 2014
    These stocks had big price moves recently, and cosidering where the price is from a technical perspective, further big moves ...
  2. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  3. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  4. Healthcare Stocks, Including Pharmacyclics, Making Big Moves ...

    December 17, 2012
    On a good day for the market, the Nasdaq has risen 0.5%, the S&P 500 has increased 0.6% and the Dow has moved up 0.5%. ...
  5. Alnylam-ISIS Venture Prices IPO - Analyst Blog

    October 5, 2012
    Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS), recently announced ...
  6. Expedia and More Big Movers on the Nasdaq on September 21, 2 ...

    September 21, 2012
    This morning, the Nasdaq has moved little, the S&P 500 has decreased 0.3% and the Dow has been relatively flat. The recent ...
  7. Healthcare Sector's Biggest Movers: HCA Holdings and More

    August 6, 2012
    The market is currently up, with the Nasdaq climbing 1%, the S&P 500 rising 0.5% and the Dow up 0.6%. The healthcare ...
  8. Isis Pharma Stays Neutral - Analyst Blog

    July 11, 2012
    We recently reiterated our Neutral recommendation on Isis Pharmaceuticals (ISIS), which carries a Zacks #3 Rank (short-term ...
  9. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  10. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  11. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
Trading Center